Tanaka T, Slamon D J, Shimada H, Shimoda H, Fujisawa T, Ida N, Seeger R C
Department of Pediatrics, National Kure Hospital, Hiroshima, Japan.
Cancer. 1991 Sep 15;68(6):1296-302. doi: 10.1002/1097-0142(19910915)68:6<1296::aid-cncr2820680619>3.0.co;2-z.
To evaluate biologic characteristics of neuroblastoma, the authors examined the expression of Ha-ras gene (Ha-ras p21) in 103 primary tumors obtained at the time of diagnosis. Higher expression of the Ha-ras p21 in tumor cells showed a significant association with lower clinical stage of the tumor at diagnosis (chi-square = 35.418, degrees of freedom [df] = 9, P less than 0.001) and survival of the patients (chi-square = 37.111, df = 3, P less than 0.001). Thirty-six (84%) of 43 patients with decreased Ha-ras p21 expression died of aggressive disease. The Ha-ras DNA was examined in the 32 tumors by Southern blot analysis. Neither augmentation nor deletion of the Ha-ras DNA was observed. Amplification of the N-myc DNA was also examined in 43 cases in comparison with Ha-ras p21 expression. N-myc amplification was detected in 12 (55%) of 22 patients who died, and 19 (86%) of the 22 patients showed a low expression of the Ha-ras p21 in tumor cells. Eighteen (86%) of 21 survivors showed a high expression of the Ha-ras p21. The expression of Ha-ras p21 was thought to be a clinically important marker for prognosis in children with neuroblastoma.
为评估神经母细胞瘤的生物学特性，作者检测了103例诊断时获取的原发性肿瘤中Ha-ras基因（Ha-ras p21）的表达。肿瘤细胞中Ha-ras p21的高表达与诊断时肿瘤的较低临床分期（卡方=35.418，自由度[df]=9，P<0.001）及患者生存率（卡方=37.111，df=3，P<0.001）显著相关。43例Ha-ras p21表达降低的患者中有36例（84%）死于侵袭性疾病。通过Southern印迹分析检测了32个肿瘤中的Ha-ras DNA。未观察到Ha-ras DNA的扩增或缺失。还比较了43例病例中Ha-ras p21表达与N-myc DNA扩增情况。在22例死亡患者中有12例（55%）检测到N-myc扩增，22例患者中有19例（86%）肿瘤细胞中Ha-ras p21表达较低。21例幸存者中有18例（86%）Ha-ras p21表达较高。Ha-ras p21的表达被认为是神经母细胞瘤患儿预后的一个重要临床标志物。
